- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02320851
Tailored Care for Somatoform Vertigo/Dizziness
Tailored Care for Somatoform Vertigo/Dizziness - From Diagnostics to Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Vertigo/dizziness (VD) is one of the most frequent problems in medicine with a one-year prevalence of 23%. Approximately 50% of the complex VD disorders (i.e., VD is the cardinal symptom and persists > 6 months) are not fully explained by an identifiable medical condition and could be labelled as somatoform vertigo/dizziness (SVD), fulfilling the criteria of somatoform disorder according to ICD-10 or DSM-IV, respectively. SVD shows a high comorbidity rate of other mental disorders, such as anxiety/phobic and depressive disorders. The majority of the patients with SVD suffer severe impairments in their daily and working lives and report a poorer quality of life compared to the patients with organic VD. Although preliminary evidence indicates that psychotherapy may be effective in these patients, the therapeutic options in the treatment of SVD remain unsatisfactory.
In this two-armed, single-centre, randomised, controlled, open superiority clinical trial, the long-term efficacy of manualised, multimodal group psychotherapy, based on integrative psychotherapy (IPT) and tailored to SVD subgroups of mental disorders will be investigated in patients with SVD compared to self-help groups (SHGs). IPT describes a differentiated psychotherapeutic approach, which combines different therapeutic techniques, such as interpersonal skills and psychodynamic aspects, self-management and symptom management skills, psychoeducation, and relaxation techniques. Within this study, IPT is tailored to SVD including its common mental comorbidity.
Patients will be recruited via routine care appointments at the German Centre for Vertigo and Balance Disorders, a specialised tertiary care unit at the Klinikum Großhadern (Ludwig-Maximilians-Universitaet, Munich).
Our principal research questions are as follows: Will IPT result in a clinically relevant improvement in vertigo/dizziness-related quality of life? Does this long-term improvement also apply to associated mental symptoms, such as depression, anxiety and somatisation, as well as balance strategies measured by posturography? Is IPT in the long term superior to moderated SVD-SHGs? The investigators hypothesise that the patients who received IPT will demonstrate greater improvement concerning their vertigo-related handicap compared to the patients from the SHGs. The investigators will also analyse the cost-effectiveness of this trial.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- SVD diagnosis
- Clinically relevant SVD (VHQ sum score > 45)
- Informed consent
Exclusion Criteria:
- Insufficient German language ability
- Insufficient cognitive abilities (Mini Mental State Test (MMST) ≤ 27)
- Severe and chronic comorbid somatic or mental disease (e.g., suicidality, severe depression, drug addiction)
- Current psychotherapeutic treatment
- Living > 50 km away from Munich
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SVD-tailored Integrative Psychotherapy (IPT)
IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress.
It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality.
In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques.
The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy.
The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
|
(see description of corresponding study arm)
|
|
Active Comparator: Self-help group (SHG)
The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions.
Those can be classified as low-level non-placebo control.
Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
|
(see description of corresponding study arm)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vertigo-related quality of life
Time Frame: Improvement at follow-up (12 months after treatment)
|
Absolute improvement of vertigo-related quality of life on the Vertigo Handicap Questionnaire (VHQ) at 12 months after the 16-week therapy sessions from VHQ at randomisation/baseline.
|
Improvement at follow-up (12 months after treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Generic quality of life
Time Frame: Improvement at follow-up (12 months after treatment)
|
Generic quality of life will be measured using the Quality of Life Questionnaire (EQ-5D).
|
Improvement at follow-up (12 months after treatment)
|
|
Severity of vertigo
Time Frame: Improvement at follow-up (12 months after treatment)
|
Severity of vertigo will be measured using the Vertigo Symptom Scale (VSS).
|
Improvement at follow-up (12 months after treatment)
|
|
Depression
Time Frame: Improvement at follow-up (12 months after treatment)
|
Depression will be measured using the Beck Depression Inventory (BDI-II).
|
Improvement at follow-up (12 months after treatment)
|
|
Anxiety
Time Frame: Improvement at follow-up (12 months after treatment)
|
Anxiety will be measured using the Beck Anxiety Inventory (BAI).
|
Improvement at follow-up (12 months after treatment)
|
|
Somatisation
Time Frame: Improvement at follow-up (12 months after treatment)
|
Somatisation will be measured using the Patient Health Questionnaire 15 (PHQ-15).
|
Improvement at follow-up (12 months after treatment)
|
|
Computerized Static Posturography and Head Impulse Test
Time Frame: Improvement at follow-up (12 months after treatment)
|
Both assessments (Computerized Static Posturography and Head Impulse Test) are introduced as state-of-the-art validated objective dimensions that address relevant core elements of the study conditions and allow for the estimation of possible intervention effects independent from the patients' self-reported outcomes.
|
Improvement at follow-up (12 months after treatment)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cost-effectiveness
Time Frame: Baseline and follow-up (12 months after treatment)
|
Cost-effectiveness will be measured as quality-adjusted life years (QALYs) derived from the EQ-5D at baseline and at 12 months after the 16-week therapy sessions.
Costs related to absence from work and health care utilisation will be obtained using a modified German version of the Trimbos/iMTA questionnaire for costs associated with Psychiatric Illness (TiC-P).
|
Baseline and follow-up (12 months after treatment)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Claas Lahmann, PD Dr. med., Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technische Universitaet, Munich
Publications and helpful links
General Publications
- Limburg K, Radziej K, Sattel H, Henningsen P, Dieterich M, Probst T, Dale R, Lahmann C. A Randomized Controlled Trial Evaluating Integrative Psychotherapeutic Group Treatment Compared to Self-Help Groups in Functional Vertigo/Dizziness. J Clin Med. 2021 May 20;10(10):2215. doi: 10.3390/jcm10102215.
- Lahmann C, Henningsen P, Dieterich M, Radziej K, Schmid G. Tailored care for somatoform vertigo/dizziness: study protocol for a randomised controlled trial evaluating integrative group psychotherapy. J Neurol. 2015 Aug;262(8):1867-75. doi: 10.1007/s00415-015-7784-6. Epub 2015 May 23.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01EO1401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.